| <strong>For neonates/infants with second‐ and/or third‐trimester antenatal exposure to rituximab, delaying live attenuated rotavirus vaccine until &gt;6 months of age is conditionally recommended.</strong> | <strong>Very low</strong>                                     | PICO 25. Should neonates/infants with second‐ and third‐trimester antenatal exposure to TNFi or rituximab receive live attenuated rotavirus vaccine in their first 6 months of life? | 964–966                  |